Irina Rivkind Koffler
Stock Analyst at Mizuho
(0.44)
# 4,227
Out of 5,126 analysts
31
Total ratings
25%
Success rate
-16.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Irina Rivkind Koffler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Assumes: Buy | $30 | $4.50 | +566.67% | 4 | Sep 5, 2019 | |
| DERM Journey Medical | Upgrades: Buy | $17 → $14 | $8.35 | +67.66% | 4 | Jun 6, 2019 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $146 → $148 | $165.50 | -10.57% | 6 | May 8, 2019 | |
| PCRX Pacira BioSciences | Upgrades: Neutral | $29 → $38 | $21.00 | +80.95% | 4 | May 6, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $61 → $63 | $51.65 | +21.97% | 2 | Dec 17, 2018 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $28 → $29 | $34.69 | -16.40% | 7 | Sep 17, 2018 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Buy | n/a | $4.56 | - | 4 | May 2, 2018 |
Evolus
Sep 5, 2019
Assumes: Buy
Price Target: $30
Current: $4.50
Upside: +566.67%
Journey Medical
Jun 6, 2019
Upgrades: Buy
Price Target: $17 → $14
Current: $8.35
Upside: +67.66%
Jazz Pharmaceuticals
May 8, 2019
Maintains: Neutral
Price Target: $146 → $148
Current: $165.50
Upside: -10.57%
Pacira BioSciences
May 6, 2019
Upgrades: Neutral
Price Target: $29 → $38
Current: $21.00
Upside: +80.95%
Supernus Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $61 → $63
Current: $51.65
Upside: +21.97%
Teva Pharmaceutical Industries
Sep 17, 2018
Maintains: Buy
Price Target: $28 → $29
Current: $34.69
Upside: -16.40%
Ironwood Pharmaceuticals
May 2, 2018
Upgrades: Buy
Price Target: n/a
Current: $4.56
Upside: -